Factual inaccuracies at Motley Fool

[mssciguy]

2. MannKind Corp.

Things didn't look much better for MannKind (NASDAQ:MNKD) in 2015. Shares of the biotech sank just over 70% due to a series of disappointing sales results for its inhaled insulin treatment, Afrezza.



Sales for Afrezza started out slowly after MannKind and partner Sanofi launched the product in February. Unfortunately, the situation only worsened from that point. Shipments of Afrezza declined each quarter.
 


By late November, MannKind CEO Hakan Edstrom was gone. That left 90-year-old founder Al Mann at the helm once again. Despite Mann's personal popularity, the change didn't leave investors feeling warm and fuzzy. The stock continued to fall in December, landing MannKind on the list of the year's worst-performing biotechs.

www.fool.com/investing/general/2015/12/28/the-worst-biotech-stocks-in-2015.aspx

[careful2invest]

Dec 28, 2015 13:09:33 GMT -5 mssciguy said:

2. MannKind Corp.

Things didn't look much better for MannKind (NASDAQ:MNKD) in 2015. Shares of the biotech sank just over 70% due to a series of disappointing sales results for its inhaled insulin treatment, Afrezza.



Sales for Afrezza started out slowly after MannKind and partner Sanofi launched the product in February. Unfortunately, the situation only worsened from that point. Shipments of Afrezza declined each quarter.
 


By late November, MannKind CEO Hakan Edstrom was gone. That left 90-year-old founder Al Mann at the helm once again. Despite Mann's personal popularity, the change didn't leave investors feeling warm and fuzzy. The stock continued to fall in December, landing MannKind on the list of the year's worst-performing biotechs.

www.fool.com/investing/general/2015/12/28/the-worst-biotech-stocks-in-2015.aspx



MNKD got ranked on the list of the worst biotechs of 2015.
Unfortunately, I can understand why.
But please look for MNKD at the end of 2016, and my bet is that it will rate in the top ten best performing biotechs of 2016!
Time will tell!

But please report 

[suebeeee1]

It appears that a few people are worried. Motley Fool, Forbes, whose next?

[mssciguy]

Dec 28, 2015 20:40:53 GMT -5 suebeeee1 said:

It appears that a few people are worried. Motley Fool, Forbes, whose next?

As long as they are "misstating the facts" no problema.


I swear though... if Mannkind were a movie, it would be a 007 film.

The first scene would feature Al Mann as Q, showing James the new inhaler.

The rest of the film would be redacted until 2017.